Coexistence of priority broadcast and unicast in peer-to-peer networks
    5.
    发明授权
    Coexistence of priority broadcast and unicast in peer-to-peer networks 有权
    优先级广播和单播在对等网络中的共存

    公开(公告)号:US09237553B2

    公开(公告)日:2016-01-12

    申请号:US13454963

    申请日:2012-04-24

    IPC分类号: H04W72/00

    CPC分类号: H04W72/005

    摘要: A method, a computer program product, and an apparatus are provided. In one configuration, the apparatus transmits a first broadcast signal including information indicating an intention to use a unicast resource for a broadcast. In addition, the apparatus transmits a second broadcast signal in the unicast resource. In another configuration, the apparatus, which is a first wireless device, receives a first broadcast signal from a second wireless device including information indicating an intention to use a unicast resource for a broadcast. In addition, the apparatus receives a first scheduling signal from the second wireless device in a scheduling resource. The first scheduling signal is for indicating a second intention to use the unicast resource for transmitting a second broadcast signal. Furthermore, the apparatus refrains from transmitting a second scheduling signal in the scheduling resource in response to the first scheduling signal.

    摘要翻译: 提供了一种方法,计算机程序产品和装置。 在一种配置中,设备发送包括表示使用广播资源的意图的信息的第一广播信号。 另外,该装置在单播资源中发送第二广播信号。 在另一种配置中,作为第一无线设备的设备从第二无线设备接收包括指示使用用于广播的单播资源的意图的信息的第一广播信号。 此外,该装置在调度资源中从第二无线装置接收第一调度信号。 第一调度信号用于指示使用单播资源发送第二广播信号的第二意图。 此外,该设备响应于第一调度信号,避免在调度资源中发送第二调度信号。

    Transmit power control based on receiver gain setting in a wireless communication network
    6.
    发明授权
    Transmit power control based on receiver gain setting in a wireless communication network 有权
    基于无线通信网络中接收机增益设置的发射功率控制

    公开(公告)号:US09014104B2

    公开(公告)日:2015-04-21

    申请号:US12264679

    申请日:2008-11-04

    摘要: Techniques for performing transmit power control based on receiver gain setting in a wireless communication network are described. In an aspect, a terminal A may estimate pathloss to another terminal B, e.g., based on a peer discovery signal received from terminal B. Terminal A may then determine a transmit power level for a peer-to-peer (PTP) signal (e.g., a paging signal) based on the estimated pathloss, a receiver gain setting at terminal B, and a target received power level for the PTP signal. Terminal A may send the PTP signal at the determined transmit power level to terminal B. In another aspect, terminal B may use different receiver gain settings in different time intervals to receive PTP signals from other terminals. Terminal A may then select a suitable time interval to send the PTP signal based on the pathloss and the different receiver gain settings used by terminal B.

    摘要翻译: 描述了基于无线通信网络中的接收机增益设置来执行发射功率控制的技术。 在一方面,终端A可以例如基于从终端B接收到的对等体发现信号来估计到另一个终端B的路径损耗。终端A然后可以确定对等(PTP)信号的发射功率电平(例如, ,寻呼信号),基于所估计的路径损耗,终端B的接收机增益设置以及PTP信号的目标接收功率电平。 终端A可以以确定的发射功率电平向终端B发送PTP信号。另一方面,终端B可以在不同的时间间隔中使用不同的接收机增益设置来从其他终端接收PTP信号。 然后,终端A可以根据终端B使用的路径损耗和不同的接收机增益设置来选择合适的时间间隔来发送PTP信号。

    METHODS OF TREATING PSORIATIC ARTHRITIS (PSA) USING IL-17 ANTAGONISTS AND PSA RESPONSE OR NON-RESPONSE ALLELES
    7.
    发明申请
    METHODS OF TREATING PSORIATIC ARTHRITIS (PSA) USING IL-17 ANTAGONISTS AND PSA RESPONSE OR NON-RESPONSE ALLELES 审中-公开
    使用IL-17拮抗剂和PSA反应或无反应物质治疗精神分裂症(PSA)的方法

    公开(公告)号:US20150064193A1

    公开(公告)日:2015-03-05

    申请号:US14358504

    申请日:2012-06-07

    申请人: Ying Wang

    发明人: Ying Wang

    摘要: The disclosure is directed to predictive methods and personalized therapies for treating psoriatic arthritis (PsA). Specifically, this disclosure relates to methods of treating a patient having PsA by selectively administering an IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab, to the PsA patient on the basis of that patient being predisposed to have a favorable response to treatment with the IL-17 antagonist. Also disclosed herein are diagnostic methods useful in predicting the likelihood that a patient having PsA will respond to treatment with an IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab.

    摘要翻译: 本公开涉及用于治疗牛皮癣关节炎(PsA)的预测方法和个性化疗法。 具体地,本公开涉及通过基于该患者倾向于具有有利的方式来选择性地向PsA患者施用IL-17拮抗剂(例如IL-17抗体,例如塞沙单抗)来治疗患有PsA的患者的方法 对IL-17拮抗剂治疗的反应。 本文还公开了可用于预测具有PsA的患者将对IL-17拮抗剂(例如IL-17抗体例如塞苏单抗)治疗反应的可能性的诊断方法。

    Bicyclic heteroaryl compounds as GPR119 modulators
    8.
    发明授权
    Bicyclic heteroaryl compounds as GPR119 modulators 有权
    双环杂芳基化合物作为GPR119调节剂

    公开(公告)号:US08940716B2

    公开(公告)日:2015-01-27

    申请号:US13696103

    申请日:2011-05-04

    摘要: Novel compounds of structure Formula I: or an enantiomer, diastereomer, tautomer, prodrug or salt thereof, wherein A, D, Di, E, J, L, n, Q, R2 and R4 are defined herein, are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. Thus, the disclosure also concerns compositions comprising these novel compounds and methods of treating diseases or conditions related to the activity of the GPR119 G protein-coupled receptor by using any of these novel compounds or a composition comprising any of such novel compounds.

    摘要翻译: 其中A,D,D,E,J,L,n,Q,R 2和R 4在本文中定义的结构式I的新型化合物或其对映异构体,非对映异构体,互变异构体,前药或其盐是GPR119G 蛋白偶联受体调节剂。 GPR119 G蛋白偶联受体调节剂可用于治疗,预防或减缓需要GPR119 G蛋白偶联受体调节剂治疗的疾病进展。 因此,本公开还涉及包含这些新化合物的组合物以及通过使用任何这些新化合物或包含任何这些新化合物的组合物来治疗与GPR119G蛋白偶联受体的活性有关的疾病或病症的方法。

    Certain crystalline hydrates, pharmaceutical compositions thereof and methods for preparation and use thereof
    9.
    发明授权
    Certain crystalline hydrates, pharmaceutical compositions thereof and methods for preparation and use thereof 有权
    某些结晶水合物,其药物组合物及其制备和使用方法

    公开(公告)号:US08916567B2

    公开(公告)日:2014-12-23

    申请号:US12938555

    申请日:2010-11-03

    申请人: Feng Que Ying Wang

    发明人: Feng Que Ying Wang

    CPC分类号: C07D263/22 A61K31/496

    摘要: At least one crystalline hydrate of (S)—[N-3-(3′-fluoro-4′-(4″-phenyl piperazinyl))phenyl-2-oxo-5-oxazolidinyl]methyl acetamide, such as those with the following formula: wherein y is a number ranging from 1/12 to 1. Also provided are methods for the preparation of such crystalline hydrates, pharmaceutical compositions comprising such crystalline hydrates, and methods for their uses.

    摘要翻译: (S) - [N-3-(3'-氟-4' - (4“ - 苯基哌嗪基))苯基-2-氧代-5-恶唑烷基]甲基乙酰胺的至少一种结晶水合物, 下式:其中y是范围从1/12至1的数字。还提供了制备这种结晶水合物的方法,包含这种结晶水合物的药物组合物,及其用途的方法。

    Hybrid hydrogel scaffold compositions and methods of use
    10.
    发明授权
    Hybrid hydrogel scaffold compositions and methods of use 有权
    混合水凝胶支架组合物和使用方法

    公开(公告)号:US08911723B2

    公开(公告)日:2014-12-16

    申请号:US13592473

    申请日:2012-08-23

    摘要: The present invention includes new hybrid hydrogel scaffolds comprised of a polyoxyethylene-polyoxypropylene (block) copolymer (a “poloxamer”) and a self-assembling peptide, which maintain the mechanical and bioactive properties of its individual constituents (as compared to when the individual constituents are scaffolds or hydrogels by themselves). The hydrogels of the invention can include a combination of materials from different origins or with different properties that provides a hybrid material that meets the multiple needs of a scaffold for tissue engineering.

    摘要翻译: 本发明包括由聚氧乙烯 - 聚氧丙烯(嵌段)共聚物(“泊洛沙姆”)和自组装肽组成的新的混合水凝胶支架,其保持其各个组分的机械和生物活性特性(与单独成分 是支架或水凝胶)。 本发明的水凝胶可以包括来自不同来源的材料或不同性质的组合,其提供满足用于组织工程的支架的多种需要的混合材料。